glucagon receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-05. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
== Consumption by region == Penis is a taboo food in many cultures, even those that consume copious offal; anthropologist Robert Rotenberg opines that the symbolic association of penis to coitus, urination and ejaculation makes consuming it off-putting. Even in areas where penis is consumed, it is typically a niche food and eaten under specific circumstances, such as when their purported health benefits are needed.
Link-N (DHLSDNYTLDHDRAIH) is a naturally occurring 16-amino acid peptide which is the N-terminal fragment derived from enzymatic cleavage of cartilage link protein. It has antiinflammatory effects and stimulates cartilage regrowth in both in vitro cultures of human cartilage tissue and animal models of arthritis, but is not known to have been tested in humans.
== Research == As of October 2025, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia and Alzheimer's disease. It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication. Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals. Seltorexant is being explored at doses of 5 to 80 mg. In the early clinical trials conducted so far, seltorexant has been found to improve depression scores on the Hamilton Depression Rating Scale in people with MDD and to improve sleep onset, total sleep time, time awake after sleep onset, and sleep efficiency in people with MDD and/or insomnia.
== Toxicity == Studies carried out on the toxicity of convulxin show that symptoms are a function of the dose. The effects of the toxin stand out through the sudden and brief duration of the symptoms after exposure. In mice, low doses (5 μg/animal) administered intravenously (I.V) elicited tachypnea, followed by apnea, within 20 seconds. The ED50 for brief duration apnea was determined to be 180 μg/kg. Higher doses (10 μg/animal) evoked intense convulsive crisis, and usually ended with the death of the animal. LD50 was determined to be 524 μg/kg. Intraperitoneal (I.P.) administration of up to 200 μg/animal proved to be ineffective. In cats, I.V. injections of 100 μg/kg showed respiratory disturbances, miosis, salivation, abdominal cramps, nystagmus, loss of equilibrium, convulsions and sometimes a brief phase of hypotonia. The ED50 dose for convulsions is 80 μg/kg. The majority of animals recovered within 30 minutes. In dogs, the effect of convulxin showed two stages. After I.V. injection of 100-125 μg/kg they became excited, barked and exhibited loss of equilibrium, respiratory disturbances, nystagmus, urination, defecation and vomiting. After recovery, two out of five animals had intermittent crisis of clonic convulsions that appeared after 24 hours and lasted until their death. The other three dogs showed periods of vivid agitation alternating with torpor. While the lethal dose in humans is not yet known, what has been discovered is that the level of toxic effects depends on the origin of the snake. As for a cure, so far a polyvalent snake antivenom is being used.
2023, Overseas Fellow of the Australian Academy of Technological Sciences and Engineering (FTSE) 2019, Othmer Gold Medal, Science History Institute and others 2018, honorary Doctorate, Utrecht University 2017, Catalyst Award, Science Club for Girls 2015, Heinz Award, Heinz Family Foundation, in the Technology, the Economy and Employment category "for her seminal work in tissue engineering and disease detection, including the cultivation of functional liver cells outside of the human body, and for her passion in promoting the advancement of women in the STEM fields." 2014, Lemelson-MIT Prize, Massachusetts Institute of Technology "for her dedication to the next generation of scientists, and groundbreaking inventions to improve human health and patient care on a global scale." 2011, BEAM (Brown Engineering Alumni Medal) Award, Brown University School of Engineering 2008, Howard Hughes Medical Institute investigator 1999, Packard Fellowship, David and Lucile Packard Foundation
Sources: en.wikipedia.org
== Ultimate Fighting Championship (UFC) == In December 2013, the UFC began a campaign to drug test their entire roster randomly all year-round. Random testing, however, became problematic for the promotion as it began to affect revenue, as fighters who had tested positive would need to be taken out of fights, which adversely affected fight cards, and therefore pay-per-view sales. If the UFC were not able to find a replacement fighter fights would have to be cancelled. According to Steven Marrocco of MMAjunkie.com, about 31% of UFC fighters subjected to random testing since the program first started have failed due to using performance-enhancing drugs. That is approximately five failed tests for every sixteen random screenings. No fighters are exempt from these tests, no matter how big or small. Former Bantamweight champion T.J. Dillashaw tested positive for EPO following his fight with Henry Cejudo in January 2019. Jon Jones, the former Heavyweight and Light Heavyweight champion in the UFC, tested positive for banned substances in June 2016. Jones urine was found to contain Clomiphene and Letrozole which lead to a one-year suspension from the sport. Another highly decorated fighter by the name of Anderson Silva tested positive for two anabolic steroids following his bout against Nick Diaz at UFC 183. The steroids were methyltestosterone and Hydrochlorothiazide. From July 2015, the UFC has advocated to all commissions that every fighter be tested in competition for every card.
=== Precursor of carnosine === β-Alanine is the rate-limiting precursor of carnosine, which is to say carnosine levels are limited by the amount of available β-alanine, not histidine. Supplementation with β-alanine has been shown to increase the concentration of carnosine in muscles, decrease fatigue in athletes, and increase total muscular work done. Simply supplementing with carnosine is not as effective as supplementing with β-alanine alone since carnosine, when taken orally, is broken down during digestion to its components, histidine (which people usually already have enough of from regular protein consumption) and β-alanine. Hence, by weight, only about 40% of the dose is available as β-alanine.
Retaliating, Gaddafi sponsored anti-government militants in Tunisia into the 1980s. Turning his attention to Algeria, in 1975 Libya signed, in Hassi Messaoud, a defensive alliance allegedly to counter alleged "Moroccan expansionism", also funding the Polisario Front of Western Sahara in its independence struggle against Morocco. Seeking to diversify Libya's economy, Gaddafi's government began purchasing shares in major European corporations like Fiat as well as buying real estate in Malta and Italy, which would become a valuable source of income during the 1980s oil slump.
== P == Pier Paolo Pandolfi (b. 1963). Italian geneticist and molecular biologist at the Desert Research Institute, Reno, known for work on pseudogenes. Jakub Karol Parnas (1884–1949). Polish-Soviet biochemist at the University of Lviv, who discovered (with Gustav Embden and Otto Fritz Meyerhof), the glycolytic pathway. Linus Pauling (1901–1994). American chemist and biochemist at Caltech, known for many advances in chemistry, including the α-helical structure of proteins. Nobel Prize in Chemistry (1954). Louis Pasteur FRS (foreign associate) (1822–1895). French biologist, microbiologist and chemist at the Pasteur Institute (Paris), who made many contributions to microbiology, stereochemistry and medicine, including the first vaccines for rabies and anthrax. Natl. Acad. Sci. USA (foreign associate). Arthur Peacocke (1924–2006). British Anglican theologian and biochemist at the University of Oxford. Max Perutz FRS (1914–2002). Austrian-British molecular biologist and X-ray crystallographer at Cambridge University, who solved the crystal structure of haemoglobin. Nobel Prize in Chemistry (1962). Samuel Victor Perry FRS (1918–2009). British biochemist at the University of Birmingham, pioneer in the biochemistry of muscle. Gösta Pettersson (b. 1937). Swedish biochemist at the University of Lund, expert on enzyme kinetics. Antoinette Pirie (1905–1991), British biochemist, ophthalmologist, and educator. Norman Wingate Pirie FRS (1907–1997), British biochemist and virologist. Rosalind Pitt-Rivers (1907–1990).
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.